For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| AMR101 | The first dose of the study medication will be given to patients after the initial flexible sigmoidoscopy. Participants will be expected to take 4 0.5 gram capsules orally, twice daily (daily dose of 4 grams) for a minimum of 8 weeks and maximum of 12 weeks | 0 | None | 1 | 81 | 20 | 81 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Ischemic right foot with thrombosis of right external iliac artery stent and common femoral artery | SYSTEMATIC_ASSESSMENT | Vascular disorders | CTCAE 5.0 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| GI Upset (i.e. nausea/gas/diarrhea/constipation/stomach ache/loss of appetite) | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | CTCAE 5.0 | View |
| COVID and Flu-like symptoms (congestion, chills, fever, body ache, headache) | SYSTEMATIC_ASSESSMENT | Infections and infestations | CTCAE 5.0 | View |
| Chest pain | SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | CTCAE 5.0 | View |
| Skin issues (acne, hyperpigmentation) | SYSTEMATIC_ASSESSMENT | Skin and subcutaneous tissue disorders | CTCAE 5.0 | View |
| Pain (joint pain, muscle aches) | SYSTEMATIC_ASSESSMENT | Musculoskeletal and connective tissue disorders | CTCAE 5.0 | View |
| Esophagitis | SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | CTCAE 5.0 | View |